Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1352
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within New Haven, Connecticut. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 397–408 of 1,352 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Active, not recruiting Phase 2 Interventional

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669
View directory record Official record
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
429
States / cities
Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Recruiting No phase listed Observational

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

NCT06551116
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
CE-10-IVD
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
37
States / cities
San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Recruiting No phase listed Observational

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545
View directory record Official record
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Active, not recruiting Phase 1 Interventional

Effects of Acute and Chronic Empagliflozin Heart Failure

NCT05553938
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
275
States / cities
Birmingham, Alabama • Clovis, California • Concord, California + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Active, not recruiting Phase 3 Interventional

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1403
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Active, not recruiting Phase 3 Interventional

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733
View directory record Official record
Conditions
Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Interventions
Niraparib, Temozolomide
Drug
Lead sponsor
Ivy Brain Tumor Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Not yet recruiting Not applicable Interventional

Effect of HBOT on Femoral Head Avascular Necrosis (AVN)

NCT06931301
View directory record Official record
Conditions
Osteonecrosis, Avascular Necrosis
Interventions
Hyperbaric Oxygen Therapy
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers

NCT04941950
View directory record Official record
Conditions
Opioid Misuse
Interventions
PlaySmart, Video Game Control
Behavioral · Other
Lead sponsor
Tyra Boomer
Other
Eligibility
16 Years to 19 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
15
States / cities
Bridgeport, Connecticut • Durham, Connecticut • East Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 2:12 AM EST
Completed Not applicable Interventional Results available

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

NCT04419857
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High-calorie formula
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 15, 2026, 2:12 AM EST